This study is about finding new ways to fight cancer, especially in children with a cancer called neuroblastoma. Neuroblastoma is tricky to treat because the cancer cells can become resistant to chemotherapy, meaning the drugs don't work as well over time. The cancer cells can switch between two different states: one where they are sensitive to drugs and one where usual cancer treatments do not work well. Here, I am proposing to understand how these cells switch between these states, which allows them to survive and avoid our best treatments. I used gene expression and epigenetic data in more than 30 different neuroblastoma cell lines to design a system called a “reporter” that can track the drug-resistant cells in neuroblastoma. Using this system, I discovered that two proteins called EP300 and CBP control the drug-resistant state. When I block these proteins using new drugs, the resistant cells became more drug-sensitive, making them easier to treat with chemotherapy. Also, I found a protein called HMGA2 that might help the cancer cells become more resistant to therapy. The next steps are to test my findings in mice with human tumors, and to learn more about how these proteins work, to be able to develop my findings into potential clinical therapies. The ultimate goal of this research is to come up with better treatments that can "reprogram" resistant cancer cells, making them more vulnerable to the drugs and helping kids with neuroblastoma have a better chance of recovery.